世界中西医结合杂志
世界中西醫結閤雜誌
세계중서의결합잡지
World Journal of Integrated Traditional and Western Medicine
2015年
11期
1549-1551
,共3页
邵国辉%闫香芹%张雷%徐爱华%侯春生
邵國輝%閆香芹%張雷%徐愛華%侯春生
소국휘%염향근%장뢰%서애화%후춘생
软肝再生颗粒%恩替卡韦%肝脏硬度值(LSM)%肝纤维化
軟肝再生顆粒%恩替卡韋%肝髒硬度值(LSM)%肝纖維化
연간재생과립%은체잡위%간장경도치(LSM)%간섬유화
Ruangan Zaisheng Granules%Entecavir%LSM%Liver Fibrosis
目的：评价软肝再生颗粒联合恩替卡韦抗肝纤维化的临床疗效。方法采用开放、非随机的方法纳入慢性乙型肝炎合并肝纤维化患者123例，分恩替卡韦单药组（A 组）、软肝再生颗粒联合恩替卡韦组（B 组）、复方鳖甲软肝片联合恩替卡韦组（C 组）3组。观察治疗前后各组肝功能、凝血功能、肝纤维化指标、肝脏超声（门静脉、脾静脉宽度，脾脏厚度）、FibroScan 肝脏硬度值（LSM）等指标的变化。结果治疗后，各组患者谷氨酸氨基转移酶（ ALT）、天门冬氨酸氨基转移酶（AST）、总胆红素（TBIL）、血清白蛋白（ALB）、凝血酶原时间（PT）均有明显改善；治疗后24周和48周，B 组、C 组上述指标恢复情况均优于 A 组（P <0.05，P <0.01）。治疗48周，脾脏厚度缩小程度 B 组、C 组均优于A 组（P <0.05）。治疗48周，B 组、C 组肝纤维化指标及 LSM 改善程度明显优于 A 组（P <0.01）。治疗48周，B 组与 C 组各个观察指标比较，差异均无统计学意义（P >0.05）。结论软肝再生颗粒联合恩替卡韦治疗可显著改善患者肝功能，对于慢性乙型肝炎导致的肝纤维化有明显疗效，可抑制肝纤维化及脾肿大进展，与复方鳖甲软肝片联合恩替卡韦效果相当。
目的：評價軟肝再生顆粒聯閤恩替卡韋抗肝纖維化的臨床療效。方法採用開放、非隨機的方法納入慢性乙型肝炎閤併肝纖維化患者123例，分恩替卡韋單藥組（A 組）、軟肝再生顆粒聯閤恩替卡韋組（B 組）、複方鱉甲軟肝片聯閤恩替卡韋組（C 組）3組。觀察治療前後各組肝功能、凝血功能、肝纖維化指標、肝髒超聲（門靜脈、脾靜脈寬度，脾髒厚度）、FibroScan 肝髒硬度值（LSM）等指標的變化。結果治療後，各組患者穀氨痠氨基轉移酶（ ALT）、天門鼕氨痠氨基轉移酶（AST）、總膽紅素（TBIL）、血清白蛋白（ALB）、凝血酶原時間（PT）均有明顯改善；治療後24週和48週，B 組、C 組上述指標恢複情況均優于 A 組（P <0.05，P <0.01）。治療48週，脾髒厚度縮小程度 B 組、C 組均優于A 組（P <0.05）。治療48週，B 組、C 組肝纖維化指標及 LSM 改善程度明顯優于 A 組（P <0.01）。治療48週，B 組與 C 組各箇觀察指標比較，差異均無統計學意義（P >0.05）。結論軟肝再生顆粒聯閤恩替卡韋治療可顯著改善患者肝功能，對于慢性乙型肝炎導緻的肝纖維化有明顯療效，可抑製肝纖維化及脾腫大進展，與複方鱉甲軟肝片聯閤恩替卡韋效果相噹。
목적：평개연간재생과립연합은체잡위항간섬유화적림상료효。방법채용개방、비수궤적방법납입만성을형간염합병간섬유화환자123례，분은체잡위단약조（A 조）、연간재생과립연합은체잡위조（B 조）、복방별갑연간편연합은체잡위조（C 조）3조。관찰치료전후각조간공능、응혈공능、간섬유화지표、간장초성（문정맥、비정맥관도，비장후도）、FibroScan 간장경도치（LSM）등지표적변화。결과치료후，각조환자곡안산안기전이매（ ALT）、천문동안산안기전이매（AST）、총담홍소（TBIL）、혈청백단백（ALB）、응혈매원시간（PT）균유명현개선；치료후24주화48주，B 조、C 조상술지표회복정황균우우 A 조（P <0.05，P <0.01）。치료48주，비장후도축소정도 B 조、C 조균우우A 조（P <0.05）。치료48주，B 조、C 조간섬유화지표급 LSM 개선정도명현우우 A 조（P <0.01）。치료48주，B 조여 C 조각개관찰지표비교，차이균무통계학의의（P >0.05）。결론연간재생과립연합은체잡위치료가현저개선환자간공능，대우만성을형간염도치적간섬유화유명현료효，가억제간섬유화급비종대진전，여복방별갑연간편연합은체잡위효과상당。
Objective To evaluate the clinical efficacy on liver fibrosis treated with ruangan zaish-eng granules and entecavir. Methods The open and non - randomization method was used to enroll 123 ca-ses of chronic hepatitis B combined with liver fibrosis. They were divided into an entecavir group(A group), the combined medication of ruangan zaisheng granules and entecavir group(B group)and the combined medi-cation of compound biejia ruangan tablets and entecair group(C group). Before and after treatment,the liver function,coagulation function,liver fibrosis indexes,liver ultrasound( portal vein,splenic venous width and spleen thickness)and FibroScan liver stiffness measurement(LSM)were observed in each group. Results After treatment,the levels of ALT,AST,TBIL,ALB and PT were all improved apparently in each group. In 24 and 48 weeks of treatment,the recovery of the above indexes in the B and C groups was better than that in the A group(P < 0. 05). In 48 weeks of treatment,the improvements in the liver fibrosis indexes and LSM in the B and C groups were apparently better than those in the A group(P < 0. 01). In 48 weeks of treatment,the differences in all the observed indexes were not significant between the B and C groups(P > 0. 05). Conclu-sion The combined medication of ruangan zaisheng granules and entecavir significantly improves liver func-tion,has apparently efficacy on liver fibrosis induced by chronic hepatitis B and inhibits the development of liver fibrosis and spleen enlargement. The efficacy is similar to that achieved by the combined medication of biejia ruangan tablets and entecair.
